BIOCON vs INDSWFTLAB: Stock Comparison

Biocon Limited vs Ind-Swift Laboratories Limited

Live data: 22 July 2026, 2:52 PM IST • Source: NSE and company filings

Biocon Limited is the larger company by market capitalisation. Biocon Limited shows a higher dividend yield and faster revenue growth, while Ind-Swift Laboratories Limited shows a lower P/E, a higher ROE and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Biocon Limited and Ind-Swift Laboratories Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BIOCON is more favourable on 4 of 13 scored metrics and INDSWFTLAB on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
BIOCON is the larger company
₹70,989 Cr vs ₹2,035 Cr
P/E Ratio
INDSWFTLAB has a lower P/E
50.25x vs 185.25x
P/B Ratio
INDSWFTLAB has a lower P/B
1.5x vs 2.1x
EPS
INDSWFTLAB has higher earnings per share
₹4.84 vs ₹2.86
Dividend Yield
BIOCON has a higher dividend yield
0.11% vs 0%
Revenue Growth (TTM YoY)
BIOCON has faster revenue growth
2.3% vs -66.6%
EPS Growth (TTM YoY)
BIOCON has faster EPS growth
-72.5% vs -94.8%
Qtr Sales Growth
INDSWFTLAB has stronger quarterly sales growth
22.8% vs 2.25%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBIOCONINDSWFTLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBIOCONINDSWFTLAB
Live Price₹435.9₹234.01
Day Change-1%-1.51%
Volume49.92 L3.77 L
52-Week High₹447.15₹248.45
52-Week Low₹331₹87.15
Distance from 52W High-2.52%-5.81%

Valuation

MetricBIOCONINDSWFTLAB
Market Cap₹70,989 Cr₹2,035 Cr
P/E Ratio185.25x50.25x
P/B Ratio2.1x1.5x
EPS₹2.86₹4.84
Book Value₹210.14₹165.77
Dividend Yield0.11%0%

Growth

MetricBIOCONINDSWFTLAB
Revenue Growth (TTM YoY)2.3%-66.6%
EPS Growth (TTM YoY)-72.5%-94.8%
Qtr Sales Growth2.25%22.8%
Qtr Profit Growth-62%9.35%

Profitability & Leverage

MetricBIOCONINDSWFTLAB
ROE1.4%3.87%
ROCE3.75%4.7%
Net Margin2.29%41.4%
Operating Margin20.4%7.03%
Debt to Equity0.45x0.01x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBIOCONINDSWFTLAB
Promoter Holding29.73% 0.17 pp42.99% 3.49 pp
FII Holding8.16% 0.64 pp13.88% 0.45 pp
DII Holding23.37% 0.7 pp0% 0.68 pp
Public Holding23.74% 0.33 pp43.12% 2.38 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Biocon Limited and Ind-Swift Laboratories Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.